Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program

被引：0
|
作者：
Spelman, Lynda [1 ]
Warren, Richard B. [2 ]
Sofen, Howard [3 ]
Imafuku, Shinichi [4 ]
Blauvelt, Andrew [5 ]
Toms, Jessica [6 ]
Buck, Alex [7 ]
Banerjee, Subhashis [6 ]
Menter, Alan [8 ]
Szepietowski, Jacek C. [9 ]
机构：
[1] Verac Clin Res, Brisbane, Qld, Australia
[2] Univ Manchester, Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
[3] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[4] Fukuoka Univ Hosp, Fukuoka, Japan
[5] Oregon Med Res Ctr, Portland, OR USA
[6] Bristol Myers Squibb, New York, NY USA
[7] Cytel Inc, Bristol Myers Squibb, Dallas, TX USA
[8] Baylor Univ, Med Ctr, Waco, TX 76798 USA
[9] Wroclaw Med Univ, Wroclaw, Poland
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：28 / 28
页数：1
相关论文
共 50 条
  • [31] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
    Armstrong, April W.
    Gooderham, Melinda
    Warren, Richard B.
    Papp, Kim A.
    Strober, Bruce
    Thaci, Diamant
    Morita, Akimichi
    Szepietowski, Jacek C.
    Imafuku, Shinichi
    Colston, Elizabeth
    Throup, John
    Kundu, Sudeep
    Schoenfeld, Steve
    Linaberry, Misti
    Banerjee, Subhashis
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 29 - 39
  • [32] Efficacy of tildrakizumab in patients with chronic plaque psoriasis: Results from long-term extensions to 2 phase 3 clinical studies
    Papp, K.
    Reich, K.
    Blauvelt, A.
    Thaci, D.
    Kimball, A.
    Sinclair, R.
    Tyring, S.
    Cichanowitz, N.
    Green, S.
    Li, Q.
    La Rosa, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 108 - 108
  • [33] Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
    Armstrong, April W.
    Augustin, Matthias
    Beaumont, Jennifer L.
    Pham, Tan P.
    Hudgens, Stacie
    Gordon, Kenneth B.
    Zhuo, Joe
    Becker, Brandon
    Zhong, Yichen
    Kisa, Renata M.
    Banerjee, Subhashis
    Papp, Kim A.
    DERMATOLOGY AND THERAPY, 2024, 14 (08) : 2235 - 2248
  • [34] Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies
    Kulasekararaj, Austin G.
    Griffin, Morag
    Langemeijer, Saskia
    Usuki, Kensuke
    Kulagin, Alexander
    Ogawa, Masayo
    Yu, Ji
    Mujeebuddin, Arshad
    Nishimura, Jun-ichi
    Lee, Jong Wook
    de Latour, Regis Peffault
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (03) : 205 - 214
  • [35] LONG-TERM SAFETY AND EFFICACY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): 2-YEAR RESULTS FROM A LONG-TERM STUDY
    Mayo, Marlyn J.
    Vierling, John M.
    Bowlus, Christopher L.
    Neff, Guy W.
    Galambos, Michael R.
    Gordon, Stuart C.
    Borg, Brian
    Levy, Cynthia
    Harrison, Stephen A.
    Thuluvath, Paul J.
    Goel, Aparna
    Shiffman, Mitchell L.
    Steinberg, Alexandra
    Xu, Emily
    Yang, Ke
    Choi, Yun-Jung
    Dickinson, Klara
    McWherter, Charles
    HEPATOLOGY, 2021, 74 : 71A - 73A
  • [36] Tofacitinib in patients with moderate to severe chronic plaque psoriasis: 2-year efficacy and safety in an open-label long-term extension study
    Paul, Carle
    Langley, Richard G.
    Valenzuela, Fernando
    Cather, Jennifer
    Gardner, Annie
    Proulx, James
    Tan, Huaming
    Wolk, Robert
    Kaur, Mandeep
    Rottinghaus, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB278 - AB278
  • [37] Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Igarashi, Atsuyuki
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Tada, Yayoi
    Nemoto, Osamu
    Rozzo, Stephen J.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 844 - 852
  • [38] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY
    Mcinnes, I.
    Kato, K.
    Magrey, M.
    Merola, J. F.
    Kishimoto, M.
    Haaland, D.
    Chen, L.
    Duan, Y.
    Liu, J.
    Lippe, R.
    Wung, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 260 - 261
  • [39] LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Baraliakos, X.
    Deodhar, A.
    van der Heijde, D.
    van den Bosch, F.
    Magrey, M.
    Maksymowych, W. P.
    Tomita, T.
    Xu, H.
    Massow, U.
    Fleurinck, C.
    Vaux, T.
    Prajapati, C.
    Shepherd-Smith, J.
    Marten, A.
    Gensler, L. S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (09) : 93 - 94
  • [40] Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
    Igarashi, Atsuyuki
    Kato, Takeshi
    Kato, Mai
    Song, Michael
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2012, 39 (03): : 242 - 252
12345